1. FDA Accepts BLA for Bevacizumab Biosimilar
The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab (Avastin), according to an announcement by Mylan during its fourth quarter 2019 earnings call. more details...


2. Bevacizumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook - Beyond the Abstract
In our recently published review, we summarize the clinical evidence and impact of bevacizumab (Avastin®), the first approved inhibitor of vascular endothelial growth factor (VEGF)-driven angiogenesis in a broad range of advanced cancer indications, including metastatic renal cell carcinoma (mRCC).1 more details...


3. Pembrolizumab Granted Accelerated FDA Approval for HCC
Pembrolizumab (Keytruda) has received an accelerated approval from the FDA for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib (Nexavar). more details...


4. News digest – cancer survival, cervical screening, immunotherapy on the NHS and US targeted drug approval
England hasn’t closed the gap on countries with the best cancer survival figures, despite improvements in cancer care and survival over the last 20 years. BBC News covered the new report, which warned that a “radical rethink” was required to help close the gap. The report highlights the need to diagnose more cancers earlier, as our news report details. more details...